Paul T. Kirschmeier

Merck & Co., Inc., Rahway, NJ, USA (United States) — United States

Medicine · Health Sciences

53h-index12.8kcitations333works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(57), Cancer Immunotherapy and Biomarkers(49), Cancer-related Molecular Pathways(38), Ovarian cancer diagnosis and treatment(36), Protein Kinase Regulation and GTPase Signaling(35)

Publications333 total

Supplemental Figures 1-8 from The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity
2023Open Access
Data from The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity
2023Open Access
Supplementary Figure Legends, Tables and Methods from The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity
2023Open Access
Data from The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity
2023Open Access
Supplemental Figures 1-8 from The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity
2023Open Access
Supplementary Figure Legends, Tables and Methods from The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity
2023Open Access
Supplementary Figures and Table legends from Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer
2023Open Access
Supplementary Table 1 from A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing
2023Open Access
Supplementary Data from Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance
2023Open Access
Table S3 from Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer
2023Open Access
Table S3 from <i>Ex Vivo</i> Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids
2023Open Access
Supplementary Data from <i>Ex Vivo</i> Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids
2023Open Access
Table S1 from <i>Ex Vivo</i> Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids
2023Open Access
Supp. Movie 3 from <i>Ex Vivo</i> Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids
2023Open Access
Supplementary Table 3 from A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing
2023Open Access
Table S4 from Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer
2023Open Access
Table S1 from Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer
2023Open Access
Supplementary Figures and Table legends from Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer
2023Open Access
Supplementary Figures 1-6 from A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing
2023Open Access
Supp. Movie 1 from <i>Ex Vivo</i> Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids
2023Open Access
page 1 of 17Next →

Frequent Co-authors

W. Robert Bishop(17), Cloud P. Paweletz(8), Donna Carr(7), Sangeetha Palakurthi(7), Linda James(6), Pasi A. Jänne(6), Stuart Black(6), Ronald J. Doll(6), Elena V. Ivanova(6), David A. Barbie(6), Tran C. Thai(5), Kwok‐Kin Wong(5), Asra Mirza(5), Yali Zhu(5), Paul Statkevich(5), Tish Hockenberry(4), William T. Windsor(4), Patrick H. Lizotte(4), Prafulla C. Gokhale(4), Shunsuke Kitajima(4)